Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | STAT1 | P42224 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2904221 | 0.88 | ALDH1A1 (0.47) | GAAKDM4EPOLBLMNAMAPT | |
| SCHEMBL5706881 | 0.86 | GAA (0.61) | GAAKDM4EPOLBLMNAMAPT | |
| SCHEMBL3846169 | 0.79 | LMNA (0.50) | GAAKDM4EPOLBLMNAMAPT | |
| SCHEMBL2723490 | 0.79 | ALDH1A1 (0.57) | GRM4GAAKDM4EPOLBLMNA | |
| SCHEMBL7291739 | 0.79 | GAA (0.50) | GAAKDM4EPOLBLMNAMAPT | |
| SCHEMBL12555538 | 0.78 | GRM4 (0.47) | GRM4GAAKDM4EPOLBLMNA | |
| SCHEMBL20258223 | 0.78 | RAB9A (0.42) | KDM4EPOLBLMNAMAPTNPC1 | |
| SCHEMBL29550233 | 0.77 | GAA (0.36) | GRM4GAAKDM4EPOLBLMNA | |
| SCHEMBL2905222 | 0.77 | RAB9A (0.40) | POLBMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15972268 | 0.76 | GRM4 (0.59) | GRM4LMNAMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010496-B1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-08-25 | — | — | EP | disclosed |
| US-20090270450-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | US | disclosed |
| EP-2084134-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2009-08-05 | — | — | EP | disclosed |
| US-20090054411-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-2010496-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008056148-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | WO | disclosed |
| WO-2007119046-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054411-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | CSF1R, CSF3R, FLT3 | GRM4 1743/4885GAA 2212/4885KDM4E 762/4885 |
| US-20090270450-A1 | CHEMICAL COMPOUNDS | CSF1R, CSF3R, FLT3 | GRM4 2406/4885GAA 1479/4885KDM4E 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.